[go: up one dir, main page]

NO20071426L - Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib - Google Patents

Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib

Info

Publication number
NO20071426L
NO20071426L NO20071426A NO20071426A NO20071426L NO 20071426 L NO20071426 L NO 20071426L NO 20071426 A NO20071426 A NO 20071426A NO 20071426 A NO20071426 A NO 20071426A NO 20071426 L NO20071426 L NO 20071426L
Authority
NO
Norway
Prior art keywords
azd2171
imatinib
human
combination therapy
therapy including
Prior art date
Application number
NO20071426A
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0421436A external-priority patent/GB0421436D0/en
Priority claimed from GB0506725A external-priority patent/GB0506725D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20071426L publication Critical patent/NO20071426L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår en fremgangsmåte for frembringelse av en antiangiogen og/eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr slik som et menneske som eventuelt blir behandlet med ioniserende stråling, spesielt en fremgangsmåte for behandling av kreft, spesielt kreft som involverer en fast tumor eller en leukemi, som omfatter å administrere AZD2171 i kombinasjon med imatinib; en farmasøytisk blanding omfattende AZD2171 og imatinib; et kombinasjonsprodukt omfattende AZD2171 og imatinib for anvendelse ved en fremgangsmåte for behandling av en menneske- eller dyrekropp ved terapi; et kit omfattende AZD2171 og imatinib; anvendelse av AZD2171 og imatinib ved fremstilling av et medikament for anvendelse ved frembringelse av en antiangiogen og/eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr slik som et menneske som eventuelt behandles med ioniserende stråling.
NO20071426A 2004-09-27 2007-03-16 Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib NO20071426L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0421436A GB0421436D0 (en) 2004-09-27 2004-09-27 Combination therapy
GB0506725A GB0506725D0 (en) 2005-04-01 2005-04-01 Combination therapy
PCT/GB2005/003672 WO2006035203A1 (en) 2004-09-27 2005-09-23 Cancer combination therapy comprising azd2171 and imatinib

Publications (1)

Publication Number Publication Date
NO20071426L true NO20071426L (no) 2007-06-18

Family

ID=35355143

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071426A NO20071426L (no) 2004-09-27 2007-03-16 Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib

Country Status (11)

Country Link
US (2) US20080015205A1 (no)
EP (1) EP1796672A1 (no)
JP (1) JP2008514576A (no)
KR (1) KR20070073813A (no)
AU (1) AU2005288736B2 (no)
BR (1) BRPI0516024A (no)
CA (1) CA2579067A1 (no)
IL (1) IL181608A0 (no)
MX (1) MX2007003506A (no)
NO (1) NO20071426L (no)
WO (1) WO2006035203A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
CA2558346A1 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
AU2006264620B2 (en) * 2005-07-06 2009-10-22 Astrazeneca Ab Combination therapy of cancer with AZD2171 and gemcitabine
KR20080077678A (ko) * 2005-12-22 2008-08-25 아스트라제네카 아베 Ａｚｄ2171 및 페메트렉시드의 조합물
BR112013024730A2 (pt) * 2011-04-01 2016-12-20 Threshold Pharmaceuticals Inc métodos para tratamento do câncer
KR101386697B1 (ko) * 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
WO2014130612A1 (en) * 2013-02-20 2014-08-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
EP4071174A1 (en) * 2016-02-15 2022-10-12 AstraZeneca AB Methods comprising fixed intermittent dosing of cediranib
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
JP2004043390A (ja) * 2002-07-12 2004-02-12 Nagoya Industrial Science Research Inst 抗腫瘍剤
US7423148B2 (en) * 2002-11-21 2008-09-09 Chiron Corporation Small molecule PI 3-kinase inhibitors and methods of their use
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
MXPA06003163A (es) * 2003-09-23 2006-06-05 Novartis Ag Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico.

Also Published As

Publication number Publication date
AU2005288736A1 (en) 2006-04-06
US20080015205A1 (en) 2008-01-17
WO2006035203A1 (en) 2006-04-06
MX2007003506A (es) 2007-05-10
BRPI0516024A (pt) 2008-08-19
CA2579067A1 (en) 2006-04-06
US20090325977A1 (en) 2009-12-31
KR20070073813A (ko) 2007-07-10
IL181608A0 (en) 2007-07-04
AU2005288736B2 (en) 2008-08-14
EP1796672A1 (en) 2007-06-20
JP2008514576A (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
NO20056170L (no) Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839
NO20064753L (no) Kombinasjonsterapi
NO20064755L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
NO20051601L (no) Kombinasjonsterapi med gemcitabin og zd6126

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application